(6-nitro-benzo[1,3]dioxol-5-yl)-acetic acid amide | 857543-43-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: (6-nitro-benzo[1,3]dioxol-5-yl)-acetic acid amide
• 英文别名: (6-Nitro-benzo[1,3]dioxol-5-yl)-essigsaeure-amid；2-(6-Nitro-1,3-benzodioxol-5-yl)acetamide
• CAS: 857543-43-2
• 化学式: C₉H₈N₂O₅
• 分子量: 224.173
• InChiKey: DEICQRFPOJCKGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (6-nitro-benzo[1,3]dioxol-5-yl)-acetic acid amide 在 盐酸 、 钯 、 溶剂黄146 作用下， 生成 (6-amino-benzo[1,3]dioxol-5-yl)-acetic acid
  参考文献：
  名称：

  Hahn; Tulus, Chemische Berichte, 1941, vol. 74, p. 500,517

  摘要：

  DOI：
• 作为产物：
  描述：

  homopiperonylic acid amide 在 硝酸 作用下， 生成 (6-nitro-benzo[1,3]dioxol-5-yl)-acetic acid amide
  参考文献：
  名称：

  Hahn; Tulus, Chemische Berichte, 1941, vol. 74, p. 500,517

  摘要：

  DOI：

文献信息

• TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：EP1866292A1

  公开（公告）日：2007-12-19
• Chemical Inhibitors of Inhibitors of Differentiation
  申请人：CHAUDHARY Jaideep

  公开号：US20090226422A1

  公开（公告）日：2009-09-10

  The present invention provides identification of inhibitors of inhibitors of differentiation (Id) for use in the treatment and prevention of diseases in mammals. The inhibitors of Id are effective alone in the treatment of a variety of cellular proliferative disorders including, but not limited to, diseases such as cancer, arthritis, age-related macular degeneration, psoriasis, neoplasms, angiomas, endometriosis, obesity, age-related macular degeneration, retinopathies, restenosis, scaring, fibrogenesis, fibrosis, cardiac remodeling, pulmonary fibrosis, scleroderma, failure associated with myocardial infarction, keloids, fibroid tumors and stenting. Additionally, these compounds are effective in blocking angiogenesis in tumor development, inducing apoptosis in malignant cells, inhibiting proliferation of cancer cells, increasing the effectiveness of chemotherapeutic agents, regulating transcriptional activity, reducing inflammation, increasing cellular differentiation, modulating ETS domain transcription factors, modulating PAX transcription factors, modulating TCF-ETS domain transcription factors, down regulating RAF-1/MAPK, upregulating JNK signaling pathways, and modulating cellular transformation.
• [EN] TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS<br/>[FR] OXYDES DE 1,2,4-TRIAZINE TRICYCLIQUES ET LEURS COMPOSITIONS A USAGE THERAPEUTIQUE DANS LES TRAITEMENTS ANTICANCEREUX
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2006104406A1

  公开（公告）日：2006-10-05

  [EN] The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
  [FR] La présente invention se rapporte à des 1-oxydes de 1,2,4-triazine tricycliques innovants et à des 1,4-dioxydes de 1,2,4-triazine tricycliques innovants de formule : (I), ainsi qu'aux analogues apparentés. Elle se rapporte également à leur préparation et à leur utilisation en tant que médicaments sélectifs de l'hypoxie et que radiosensibilisants destinés au traitement du cancer, seuls ou en combinaison avec une radiothérapie et/ou d'autres médicaments anticancéreux.